Reports from Kumamoto University, Medical Department advance knowledge in HIV/AIDS

According to a study from Honjo, Japan, "We generated a novel nonpeptidic protease inhibitor (PI), GRL-02031, by incorporating a stereochemically defined fused cyclopentanyltetrahydrofuran (Cp-THF) which exerted potent activity against a wide spectrum of human immunodeficiency virus type 1 (HIV-1) isolates, including multidrug-resistant HIV-1 variants. GRL-02031 was highly potent against laboratory HIV-1 strains and primary clinical isolates, including subtypes A, B, C, and E (50% effective concentration [EC50] range, 0.015 to 0.038 mc M), with minimal cytotoxicity (50% cytotoxic concentration, >100 mc M in CD4+ MT-2 cells), although it was less active against two HIV-2 strains...

Want to see the full article?

• Purchase this article for only $3.00